Alumis (ALMS) and Acelyrin (SLRN) announced a definitive merger agreement under which Alumis and Acelyrin will merge in an all-stock ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

The new company is created to effect the merger, and a stock ticker symbol is assigned to the SPAC. For example, Lucid Motors merged with Churchill Capital Corp. IV (NYSE: CCIV) to effect a $4.4 ...

Under the terms of the deal, ACELYRIN shareholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock. Once the deal closes, Alumis stockholders will own about ...

It raised its dividend for the first time since 2021. Is Albertsons stock a buy after failed merger with Kroger? The mega deal with grocery store chain Kroger fell apart in December. Since its ...

Getty and Shutterstock are merging to counter declining fortunes in a maturing stock photography industry and face significant threats from generative AI and free platforms. The merger aims to ...

Additionally, such a merger could create volatility in commodity ... portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of ...

Alumis (ALUM) stock dropped while Acelyrin (SLRN) stock gained in the premarket as the biopharma companies announced an all-stock merger deal. Read more here.